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To the Editor: 
Recently, there has been growing interest in statistical algorithms designed for tackling intra-sample 
cellular heterogeneity (ISCH) in Epigenome-Wide Association Studies (EWAS) 1. Such algorithms can be 
broadly classified as either reference-based (if they use reference DNA methylation (DNAm) profiles of 
representative cell types) 2, or reference-free (if they don’t require such reference profiles) 3-6. Reference-
free methods can be further subdivided into those that use the phenotype of interest in the inference 
process (this includes algorithms such as Surrogate Variable Analysis (SVA) 4, 7 and RefFreeEWAS 3), and 
those that do not (e.g.  EWASher 5 and RUV 6). Comparisons between these different inference-paradigms 
is of paramount interest in order to inform the EWAS community on how best to approach the ISCH 
problem.   
A recent study by Rahmani et al 8 presented a reference-free algorithm called ReFACTor, and suggested 
that it leads to improved estimates of cell type composition and power when compared to other 
competing algorithms. However, the approach on which ReFACTor is based could incorrectly remove the 
biological signal of interest if the latter is stronger than the variation associated with cell-type 
composition.  We confirmed this by applying  ReFACTor to additional datasets. Below we discuss key issues 
which any future methodological comparative study should pay particular attention to, to ensure robust 
and meaningful conclusions, which can then be used to guide the EWAS community. 
In principle, an advantage of a reference-free method like ReFACTor is that it is applicable to any tissue 
type. It is important therefore to assess performance in tissue types other than blood, because 
assumptions valid in one tissue type may not be valid in others. For instance, ReFACTor relies on the 
assumption that the top components of variation are associated with changes in cell-type composition, 
effectively using these components to construct variables that account for variations in cell-type. While 
this assumption may be valid for EWAS conducted in whole blood 9, the generality of it to other tissue 
types remains to be shown.  In essence, ReFACTor is similar in concept to Remove Unwanted Variation 
(RUV) 6 in that both select control genes that capture confounding variation. However, blind application 
of ReFACTor could lead to a substantial loss of power if control genes are misidentified as those carrying 
biological signal.  Although these problems represent an intrinsic limitation of any reference-free method, 
it will be particularly acute for methods like ReFACTor or EWASher 5, which do not use phenotype 
information from the outset. We used normal mammary epithelial and breast cancer cell-line data to 
define a gold-standard set of true positive features and a breast cancer tissue EWAS for the evaluation of 
several methods.  SVA 4 had a much better control of power,outperforming ReFACTor by as much as 70% 
(Table-1, Supplementary Data 1-2, Supplementary Software 1-2). While specificity is harder to estimate, 
the improved power of SVA over ReFACTor was at the expense of only a 10-20% lower specificity (Table 
1). ReFACTor’s loss of power in our cancer-tissue EWAS was due to the top components of variation 
correlating more strongly with disease status than with cell-type composition (Supplementary figure 1). 
Only lower-ranked components correlated with adipose cell content, which is the major source of cell-
type variation in breast tissue (Supplementary figure 1). This problem could in principle be circumvented 
by applying ReFACTor to the normal samples only, as suggested by Rahmani et al., but it remains to be 
tested on more datasets. Hence, application of a method like ReFACTor demands that one must carefully 
consider the tissue and biological context. 
A second key issue concerns the evaluation of a reference-free method in terms of modelling cell-type 
composition. In the case of ReFACTor, estimated components were added successively to a linear model, 
leading to an improvement in the fraction of variance explained (summarized with R2 values). To avoid 
the problem of overfitting we used a nested models likelihood ratio test (LRT) (or adjusted R2 values). We 
found little justification for the successive addition of components (Supplementary Methods, 
Supplementary Software 1-4, Supplementary Data 3, Supplementary figure 2). Alternatively, one could 
attempt to estimate the number of significant components of variation. In our hands entering such 
estimates into ReFACTor leads to a drop of as much as 20% in R2 values, resulting in reduced modeling 
performance, when compared to reference-based methods (Supplementary figures 3-4). This indicates 
that application of ReFACTor with all estimated components could lead to overfitting. We confirmed this 
further using training/test set partitions (Supplementary figure 5).   
Another issue is the use of a single or limited number of datasets with matched FACS data to benchmark 
a novel method against existing algorithms. In our experience, the complexity and unknown nature of the 
sources of variation in EWAS data requires many datasets to reach unbiased conclusions. To demonstrate 
this, we performed cell composition analysis for an independent whole blood dataset, as well as an 
extensive analysis encompassing five different in-silico mixture experiments, drawing on 1573 purified 
blood cell-types from over 6 different studies (Supplementary table 1). These analyses demonstrate the 
strength of Houseman’s reference-based method compared to ReFACTor (Supplementary figure 2, 
Supplementary figures 6-9). Further issues, including inappropriate choice of gold-standards in real data 
are discussed in Supplementary Methods. 
In summary, we suggest that future studies proposing novel methods ought to (i) provide comprehensive 
comparisons to existing algorithms, (ii) use biological scenarios and datasets that allow objective 
comparisons, and (iii) when applicable, include tissues other than blood. We provide some 
recommendations in the accompanying Supplementary Information and Supplementary table 2. Briefly, 
we recommend reference-based methods for scenarios where the composition of tissues is relatively well 
known, and reference-free methods like SVA or RefFreeEWAS when reference DNAm profiles are not 
available. We point out that our recommendations are based on currently available data sets and 
approaches, which may change as the field continues to evolve. 
 
Data Availability: All data analyzed is publicly available. See Supplementary Information for detailed 
accession numbers for all datasets analysed. 
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Tables 
 Unadj. SVA ReFACTor 
(k=6,ncp=6) 
ReFACTor 
(k=6,ncp=15) 
ReFACTor 
(k=10,ncp=10) 
ReFACTor 
(k=10,ncp=15) 
SE 
(P < 0.05) 
0.90 
(n=20876) 
0.83 
(n=19356) 
0.09  
(n=2066) 
0.02 
(n=412) 
0.02  
(n=410) 
0.02 
(n=410) 
SE 
(FDR < 0.05) 
0.89  
(n=20667) 
0.81 
(n=18743) 
0.04  
(n=835) 
≈0 
(n=23) 
≈0  
(n=13) 
≈0  
(n=13) 
SP 
(P < 0.05) 
0.53 
(n=16057) 
0.70 
(n=10274) 
0.62  
(n=12793) 
0.92 
(n=2603) 
0.95  
(n=1582) 
0.95 
(n=1582) 
SP 
(FDR < 0.05) 
0.58 
(n=14146) 
0.75 
(n=8436) 
0.84 
(n=5571) 
0.99 
(n=115) 
≈1 
(n=11) 
≈1 
(n=11) 
Table-1: Table comparing the relative sensitivity (SE) and specificity (SP) of ReFACTor (for 4 different choices of k and 
ncp parameters: ncp=15, estimated using RMT 7 as described in Supplemental Methods), to SVA and to an 
unadjusted analysis. Sensitivities and Specificites were estimated using a set of n=23258 true positives and 34078 
true negatives, respectively, and are shown at an unadjusted P < 0.05 and FDR corrected < 0.05. 
 
